Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertain
I'm PortAI, I can summarize articles.
Sunshine Guojian Pharmaceutical announced that the company has signed an exclusive development, production, and commercialization licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody product 707. The agreement will take effect on July 24, 2025, and Pfizer has registered two global Phase III clinical trials on ClinicalTrials.gov. However, due to milestone payments being subject to specific conditions, there is uncertainty regarding the final payment, and investors should be aware of the risks
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments